- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 495/08 - Bridged systems
Patent holdings for IPC class C07D 495/08
Total number of patents in this class: 99
10-year publication summary
|
2
|
9
|
6
|
10
|
2
|
3
|
3
|
8
|
4
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3737 |
7 |
| Genentech, Inc. | 4114 |
5 |
| Universitat Rovira I Virgili | 110 |
4 |
| Bristol-myers Squibb Company | 4757 |
3 |
| Janssen Pharmaceutica N.V. | 3160 |
3 |
| Merck Patent GmbH | 5735 |
3 |
| Georgia Tech Research Corporation | 2963 |
3 |
| Alnylam Pharmaceuticals, Inc. | 1180 |
3 |
| Eli Lilly and Company | 4101 |
3 |
| Fundació Institut Català D'investigació Química (iciq) | 48 |
3 |
| The Global Alliance for TB Drug Development, Inc. | 42 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3010 |
3 |
| Sanofi | 4319 |
3 |
| Merck Sharp & Dohme Corp. | 2183 |
2 |
| Astellas Pharma Inc. | 1039 |
2 |
| Schering Corporation | 344 |
2 |
| Tokyo Ohka Kogyo Co., Ltd. | 1569 |
2 |
| Cerevel Therapeutics, LLC | 37 |
2 |
| HTG Molecular Diagnostics, Inc. | 34 |
2 |
| USA Elixiria Biotech Inc | 3 |
2 |
| Other owners | 39 |